Ninety One UK Ltd Raises Stake in Johnson & Johnson (NYSE:JNJ)

Ninety One UK Ltd increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 0.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,436,013 shares of the company's stock after acquiring an additional 12,867 shares during the quarter. Johnson & Johnson comprises approximately 2.1% of Ninety One UK Ltd's portfolio, making the stock its 13th biggest position. Ninety One UK Ltd owned 0.18% of Johnson & Johnson worth $695,301,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. DORCHESTER WEALTH MANAGEMENT Co increased its holdings in Johnson & Johnson by 0.6% in the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company's stock worth $11,758,000 after buying an additional 414 shares in the last quarter. OneAscent Financial Services LLC grew its stake in shares of Johnson & Johnson by 82.8% during the 4th quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company's stock valued at $1,542,000 after purchasing an additional 4,457 shares during the period. TrueMark Investments LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $1,458,000. RAM Investment Partners LLC grew its stake in shares of Johnson & Johnson by 4.5% during the 4th quarter. RAM Investment Partners LLC now owns 1,688 shares of the company's stock valued at $265,000 after purchasing an additional 73 shares during the period. Finally, RFG Advisory LLC grew its stake in shares of Johnson & Johnson by 12.6% during the 3rd quarter. RFG Advisory LLC now owns 18,758 shares of the company's stock valued at $2,921,000 after purchasing an additional 2,102 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $1.03 during trading hours on Wednesday, reaching $148.53. The stock had a trading volume of 9,665,941 shares, compared to its average volume of 7,388,979. The firm has a market cap of $357.92 billion, a price-to-earnings ratio of 9.17, a PEG ratio of 2.46 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The firm has a 50-day moving average of $155.83 and a 200-day moving average of $155.51.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts' consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the previous year, the business earned $2.68 earnings per share. The business's revenue for the quarter was up 2.3% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.34%. The ex-dividend date is Monday, May 20th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.19. Johnson & Johnson's dividend payout ratio (DPR) is presently 29.68%.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company's stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company's stock, valued at $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm's stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company's stock, valued at $22,099,078.32. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on JNJ. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, February 6th. Morgan Stanley lowered their price target on Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 17th. Raymond James upped their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the stock an "outperform" rating in a report on Wednesday, January 3rd. Royal Bank of Canada decreased their price objective on Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday, April 17th. Finally, Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.